RT @RoussosTorres: 1/3: Very excited to announce the publication of our clinical trial of #immunotherapy in advanced solid tumors! https:/…
555 followers
72 followers
“The objective response rate by RECIST 1.1 was 16%, including a complete response in triple-negative breast cancer. A statistically significant increase in CD8/FoxP3 ratio was seen following the addition of ICIs to entinostat, but not post-entinostat alone
369 followers
Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844) https://t.co/XYBnufmDhM
192 followers
Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors. https://t.co/TTUQm561a8